Bone marrow-derived mesenchymal stem cells for treatment of aplastic anemia

The purpose of this study was to determine whether bone marrow-derived mesenchymal stem cell (MSC) infusion can treat refractory or relapsed aplastic anemia. Patients with relapsed aplastic anemia were  treated with a conventional immunosuppressive regimen (anti-thymocyte globulin plus cyclosporine) combined with intravenous infusion of allogeneic, unrelated bone marrow mesenchymal stem cells.